COVID-19 pandemic
South Africa is expected to begin a trial of the NVX-CoV2373, a vaccine candidate produced by Novavax. Around 2,904 volunteers are expected to be selected, who are aged from 18 to 64 years.
Sources: MyJoyOnline
Changes
- South Africa is expected to begin a trail of the NVX-CoV2373, a vaccine candidate produced by Novavax. Around 2,904 volunteers are expected to be selected, who are aged from 18 to 64 years.
- South Africa is expected to begin a trial of the NVX-CoV2373, a vaccine candidate produced by Novavax. Around 2,904 volunteers are expected to be selected, who are aged from 18 to 64 years.